New MRI-Guided brain zaps aim to ease anxiety in days
NCT ID NCT07640945
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a faster version of brain stimulation for generalized anxiety disorder. Instead of weeks of treatment, participants receive five sessions per day for five days. The stimulation is guided by each person's MRI scan to target a specific brain area linked to anxiety. The trial will include 75 adults aged 18-65 to see if this approach safely reduces anxiety symptoms more quickly than standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- continuous theta burst stimulation (cTBS) via transcranial magnetic stimulation (TMS) device
- What this could lead to
- If it works, this could provide a faster treatment option for generalized anxiety disorder, reducing symptoms in days instead of weeks.
- What could go wrong
- This is an early-stage trial with only 75 people, so results may not apply to everyone. The treatment is intensive (5 sessions per day for 5 days) and may cause discomfort or side effects like headache.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Outpatients or inpatients at the Second Xiangya Hospital who are confirmed by two experienced psychiatrists to meet the International Classification of Diseases 11th Revision (ICD-11) diagnostic criteria for generalized anxiety disorder. * Aged 18 to 65 years, regardless of gender. * Right-handed. * Junior high school education or above, with the ability to provide informed consent and complete cognitive assessments. * Able to receive anti-anxiety treatment during the follow-up period according to the instructions of outpatient or inpatient physicians. * Hamilton Anxiety Rating Scale (HAMA) score ≥14 and Patient Health Questionnaire-15 (PHQ-15) score ≥5. Exclusion Criteria: * Presence of psychotic symptoms. * Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, current psychiatric symptoms, or post-traumatic stress disorder based on SCID-5 assessment, either currently or within the past year. * Organic brain disease or severe somatic diseases, such as thyroid disease, lupus, diabetes, lung disease, liver disease, kidney disease, infection, or major trauma. * Intracranial implants. * Clinically significant sensory impairments that cannot be corrected, such as color blindness or hearing impairment. * Pregnant or breastfeeding women. * Positive urine drug screen. * Abnormal thyroid function tests. * Personal history of epilepsy or family history of epilepsy. * Receipt of physical therapy within the past six months, such as repetitive transcranial magnetic stimulation or electroconvulsive therapy. * Suspected or confirmed history of alcohol or drug dependence. * Use of anticoagulants, such as heparin or warfarin, corticosteroids, or thyroid disease treatments within the past three months. * Current use of psychoactive medications. * Receipt of neurocognitive assessments similar to those used in this study within the past 12 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Generalized anxiety disorder (GAD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Magnetic brain zaps may quiet anxiety: device trial puts it to the test
- Can the right electric pulse calm chronic worry?
- A brief therapy that builds on strengths may calm young adult anxiety
- Can brain and blood data predict Anxiety's future?
- Can a daily microdose of psilocybin calm chronic anxiety?
- Can online therapy or parent coaching ease childhood anxiety? a head-to-head trial aims to find out.